Ovid Therapeutics Inc. Common Stock (OVID)
Stock · NASDAQ · Health Care
$2.17as of 10/16/2026
Price chart
Active signals
OVID Signal Track Record
How signals performed across all stocks →What OVID's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 47 | -2.2% | 47% | September 18, 2026 |
| Bollinger Band Breakout | 24 | +2.8% | 54% | August 13, 2026 |
| Bollinger Band Breakdown | 22 | +0.4% | 50% | September 23, 2026 |
| 200-Day Moving Average TouchActive now | 7 | +6.2% | 71% | July 22, 2025 |
| Any 20-session window (baseline) | +1.7% | 53% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About OVID
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 23
- Website
- ovidrx.com/
Fundamentals
- 1-day range
- $2.16$2.3
- Market cap
- $494.60M
- P/E (trailing)
- —
- P/E (forward)
- -5.96
- EPS (trailing)
- $-0.25
- Dividend yield
- —
- Beta
- 0.28
- Avg. volume
- 1.58M
How Ovid Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 18, 2026 · via SEC EDGAR / Finnhub
Forecasts
10 analyst ratings
Ovid Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- OVIDOvid Therapeutics Inc. Common Stock$2.15▼ 4.87%Market cap $494.60MP/E —$1.18$3.11
- AQSTAquestive Therapeutics Inc. Common Stock$3.78▼ 6.90%Market cap $491.83MP/E —$2.93$7.55
- TENXTenax Therapeutics Inc. Common Stock$1.36▼ 9.93%Market cap $498.11MP/E —$1.31$19.4
- BIOABioAge Labs Inc. Common Stock$4.84▼ 9.53%Market cap $500.98MP/E —$5.04$25.96
- EOLSEvolus Inc. Common Stock$7.1▼ 6.21%Market cap $487.98MP/E —$3.86$9.31
- QTTBQ32 Bio Inc. Common Stock$7.52▼ 3.22%Market cap $482.18MP/E 7.95$1.91$23.57
- EVMNEvommune Inc. Common Stock$5.17▼ 12.82%Market cap $481.93MP/E —$6.52$33.2
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| OVID Ovid Therapeutics Inc. Common Stock | $494.60M | — | $2.15 | ▼ 4.87% | $1.18$3.11 |
| AQST Aquestive Therapeutics Inc. Common Stock | $491.83M | — | $3.78 | ▼ 6.90% | $2.93$7.55 |
| TENX Tenax Therapeutics Inc. Common Stock | $498.11M | — | $1.36 | ▼ 9.93% | $1.31$19.4 |
| BIOA BioAge Labs Inc. Common Stock | $500.98M | — | $4.84 | ▼ 9.53% | $5.04$25.96 |
| EOLS Evolus Inc. Common Stock | $487.98M | — | $7.1 | ▼ 6.21% | $3.86$9.31 |
| QTTB Q32 Bio Inc. Common Stock | $482.18M | 7.95 | $7.52 | ▼ 3.22% | $1.91$23.57 |
| EVMN Evommune Inc. Common Stock | $481.93M | — | $5.17 | ▼ 12.82% | $6.52$33.2 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Wolfe Research Initiates Coverage On Ovid Therapeutics with Outperform Rating, Announces Price Target of $5benzinga · 10/15/2026
- Cantor Fitzgerald Initiates Coverage On Ovid Therapeutics with Overweight RatingBenzinga · 10/9/2026
- Ovid Therapeutics (OVID) Stock Gets Fair Value Boost As Analysts Focus On OV329Yahoo · 10/8/2026
- Guggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7Benzinga · 10/6/2026
- What's going on in today's after hours sessionChartMill · 10/1/2026
- Vail Resorts, Inventiva And Other Big Stocks Moving Lower In Tuesday’s Pre-Market SessionBenzinga · 9/29/2026
- Ovid Therapeutics (OVID) Cashes In One Bet To Fund Its Next TwoYahoo · 9/12/2026
Insider Activity
Insider Actions →- Charles Ross Carter · July 6, 2026 · Grant50.0K
- Greka Anna · June 15, 2026 · Grant130.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 104.64M
- Total value held
- $231.92M
- Institutional holders
- 100
- Unknown10.71M
- Unknown10.71M
- Unknown10.64M
- Unknown9.92M
- Unknown6.16M
- Unknown5.53M
- Unknown5.26M
- Unknown4.54M
- Unknown4.17M
- Unknown3.57M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Ovid Therapeutics shares decline in pre-market session
Ovid Therapeutics stock fell during Tuesday's pre-market trading, joining a group of larger companies experiencing similar declines. The drop brings the stock closer to its recent support level of $2.38. This movement occurs while the average analyst price target remains significantly higher at $5.92.
Ovid Therapeutics shares decline in pre-market session. Ovid Therapeutics stock fell during Tuesday's pre-market trading, joining a group of larger companies experiencing similar declines. The drop brings the stock closer to its recent support level of $2.38. This movement occurs while the average analyst price target remains significantly higher at $5.92.